2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart A
![The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases | SpringerLink The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10557-021-07248-1/MediaObjects/10557_2021_7248_Fig1_HTML.png)
The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases | SpringerLink
![Antihypertensive Class and Cardiovascular Outcomes in Patients With HIV and Hypertension | Hypertension Antihypertensive Class and Cardiovascular Outcomes in Patients With HIV and Hypertension | Hypertension](https://www.ahajournals.org/cms/asset/6de336ae-8c0c-4041-bbb5-975f81222519/hypertensionaha.120.16263.fig04.jpg)
Antihypertensive Class and Cardiovascular Outcomes in Patients With HIV and Hypertension | Hypertension
![PDF) The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: Possible genetic and cell-signaling mechanisms PDF) The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: Possible genetic and cell-signaling mechanisms](https://i1.rgstatic.net/publication/234071164_The_roles_of_beta-adrenergic_receptors_in_tumorigenesis_and_the_possible_use_of_beta-adrenergic_blockers_for_cancer_treatment_Possible_genetic_and_cell-signaling_mechanisms/links/02d677c00cf29352103291f1/largepreview.png)
PDF) The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: Possible genetic and cell-signaling mechanisms
![First-line renin–angiotensin system inhibitors vs. other first-line antihypertensive drug classes in hypertensive patients with type 2 diabetes mellitus | Journal of Human Hypertension First-line renin–angiotensin system inhibitors vs. other first-line antihypertensive drug classes in hypertensive patients with type 2 diabetes mellitus | Journal of Human Hypertension](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41371-018-0066-x/MediaObjects/41371_2018_66_Fig7_HTML.jpg)
First-line renin–angiotensin system inhibitors vs. other first-line antihypertensive drug classes in hypertensive patients with type 2 diabetes mellitus | Journal of Human Hypertension
![Risk/Benefit Assessment of β-Blockers and Diuretics Precludes Their Use for First-Line Therapy in Hypertension | Circulation Risk/Benefit Assessment of β-Blockers and Diuretics Precludes Their Use for First-Line Therapy in Hypertension | Circulation](https://www.ahajournals.org/cms/asset/0c97f0dd-3e7d-430d-ba89-e5b52550fcc6/24ff6.jpg)
Risk/Benefit Assessment of β-Blockers and Diuretics Precludes Their Use for First-Line Therapy in Hypertension | Circulation
![Frontiers | Chronic Kidney Disease Progression Risk in Patients With Diabetes Mellitus Using Dihydropyridine Calcium Channel Blockers: A Nationwide, Population-Based, Propensity Score Matching Cohort Study Frontiers | Chronic Kidney Disease Progression Risk in Patients With Diabetes Mellitus Using Dihydropyridine Calcium Channel Blockers: A Nationwide, Population-Based, Propensity Score Matching Cohort Study](https://www.frontiersin.org/files/Articles/786203/fphar-13-786203-HTML-r1/image_m/fphar-13-786203-t002.jpg)
Frontiers | Chronic Kidney Disease Progression Risk in Patients With Diabetes Mellitus Using Dihydropyridine Calcium Channel Blockers: A Nationwide, Population-Based, Propensity Score Matching Cohort Study
![PDF) Factors associated with 30-day readmission of patients with heart failure from a Japanese administrative database PDF) Factors associated with 30-day readmission of patients with heart failure from a Japanese administrative database](https://i1.rgstatic.net/publication/283261858_Factors_associated_with_30-day_readmission_of_patients_with_heart_failure_from_a_Japanese_administrative_database/links/5643d8c308aef646e6c8e0da/largepreview.png)
PDF) Factors associated with 30-day readmission of patients with heart failure from a Japanese administrative database
![2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Journal of the American College of 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Journal of the American College of](https://www.jacc.org/cms/asset/d31a5f8b-a59e-4510-ab96-ce97f982fb71/gr11.jpg)
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Journal of the American College of
![The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases | SpringerLink The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10557-021-07248-1/MediaObjects/10557_2021_7248_Fig2_HTML.png)
The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases | SpringerLink
![Frontiers | Incident Heart Failure in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Frontiers | Incident Heart Failure in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention](https://www.frontiersin.org/files/Articles/727727/fcvm-08-727727-HTML/image_m/fcvm-08-727727-g005.jpg)
Frontiers | Incident Heart Failure in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
![Risk/Benefit Assessment of β-Blockers and Diuretics Precludes Their Use for First-Line Therapy in Hypertension | Circulation Risk/Benefit Assessment of β-Blockers and Diuretics Precludes Their Use for First-Line Therapy in Hypertension | Circulation](https://www.ahajournals.org/cms/asset/f17c41b5-bf75-4d7c-9063-a858f922f923/24ff1.jpeg)